Sector News

Regeneron tops best science employer poll again

October 17, 2014
Life sciences
Regeneron has once again come top of Science magazine’s top 20 employers survey, followed by Novo Nordisk and Roche’s Genentech unit.
 
The poll is based on 5,394 responses from readers of Science and employees in the biotechnology and pharmaceutical industry, who were asked to rank the best employers on a number of characteristics. The categories included ‘’innovative leader in the industry’, treats employees with respect’, ‘has loyal employees’ and ‘is socially responsible’.
 
Regeneron came out as the top company for the third year in a row, while Novo leapt to second from 11th place last year. They were followed by Genentech, Vertex (4), Eli Lilly (5), AbbVie (7) and Roche itself, up eight places from last year to eighth.
 
Biogen Idec came in at 10th, while Novartis slipped three places to 11th. Newcomers to the list were Actelion (14), Johnson & Johnson (19) and Merck KGaA (20). The other pharma players in the top 20 are Boehringer Ingelheim (13, down from 9), Celgene (up two places to 15), Bayer (up four to 16) and Amgen, which rose one place to 18th.
 
Science claims that “a common thread runs through the top 20 list: give employees the intellectual freedom and support necessary to pursue high-risk/high-reward goals – and they’ll deliver”. The journal says that by adding “a noble mission” to this, “employers can create a positive feedback loop that maximises employees’ drive and dedication as well as company profits”.
 
By Kevin Grogan
 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach